fluoxetine has been researched along with MS (Multiple Sclerosis) in 18 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS)." | 7.96 | [The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro]. ( Boyko, AN; Krivenko, LV; Melnikov, MV; Pashenkov, MV; Rogovskii, VS; Sviridova, AA, 2020) |
| "Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS)." | 3.96 | [The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro]. ( Boyko, AN; Krivenko, LV; Melnikov, MV; Pashenkov, MV; Rogovskii, VS; Sviridova, AA, 2020) |
| "This study was carried out to clarify the effects of the antidepressant fluoxetine, a selective serotonin reuptake inhibitor, for its potential use in autoimmune diseases like multiple sclerosis in a rat model of experimental autoimmune encephalomyelitis (EAE)." | 3.78 | Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. ( Liu, S; Liu, XJ; Lu, T; Qiu, G; Wang, X; Wu, Y; Yuan, XQ, 2012) |
| "Fluoxetine is a selective serotonin reuptake inhibitor, which also has an immunomodulatory effect." | 1.62 | The role of 5-HT ( Boyko, A; Kudrin, V; Melnikov, M; Pashenkov, M; Rogovskii, V; Sviridova, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Foley, P | 1 |
| Parker, RA | 2 |
| de Angelis, F | 2 |
| Connick, P | 2 |
| Chandran, S | 2 |
| Young, C | 1 |
| Weir, CJ | 2 |
| Chataway, J | 2 |
| Grech, LB | 2 |
| Butler, E | 2 |
| Stuckey, S | 2 |
| Hester, R | 2 |
| Mostert, JP | 3 |
| De Keyser, J | 3 |
| Plantone, D | 1 |
| Doshi, A | 1 |
| John, N | 1 |
| Stutters, J | 1 |
| MacManus, D | 1 |
| Prados Carrasco, F | 1 |
| Barkhof, F | 1 |
| Ourselin, S | 1 |
| Braisher, M | 1 |
| Ross, M | 1 |
| Cranswick, G | 1 |
| Pavitt, SH | 1 |
| Giovannoni, G | 1 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Hawkins, C | 1 |
| Sharrack, B | 1 |
| Bastow, R | 1 |
| Stallard, N | 1 |
| Krivenko, LV | 1 |
| Sviridova, AA | 1 |
| Melnikov, MV | 1 |
| Rogovskii, VS | 1 |
| Boyko, AN | 1 |
| Pashenkov, MV | 1 |
| Sviridova, A | 1 |
| Rogovskii, V | 1 |
| Kudrin, V | 1 |
| Pashenkov, M | 1 |
| Boyko, A | 1 |
| Melnikov, M | 1 |
| Ha-Vinh, P | 1 |
| Nauleau, S | 1 |
| Clementz, M | 1 |
| Régnard, P | 1 |
| Sauze, L | 1 |
| Clavaud, H | 1 |
| Sijens, PE | 2 |
| Irwan, R | 1 |
| Potze, JH | 1 |
| Oudkerk, M | 2 |
| Patti, F | 1 |
| Leone, C | 1 |
| D'Amico, E | 1 |
| Yuan, XQ | 1 |
| Qiu, G | 1 |
| Liu, XJ | 1 |
| Liu, S | 1 |
| Wu, Y | 1 |
| Wang, X | 1 |
| Lu, T | 1 |
| Otton, SV | 1 |
| Wu, D | 1 |
| Joffe, RT | 1 |
| Cheung, SW | 1 |
| Sellers, EM | 1 |
| Nahas, Z | 1 |
| Arlinghaus, KA | 1 |
| Kotrla, KJ | 1 |
| Clearman, RR | 1 |
| George, MS | 1 |
| Shafey, H | 1 |
| Flax, JW | 1 |
| Gray, J | 1 |
| Herbert, J | 1 |
| Browning, WN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| 5-HTSEP: Serotonin 5-HT7 Receptor Implication in the Inflammatory Mechanisms in Multiple Sclerosis[NCT04546698] | 78 participants (Actual) | Observational | 2020-09-07 | Completed | |||
| RESEPTOR 5-HT7 : Interest of the 5-HT7 Serotonin Receptor as a Biomarker in Multiple Sclerosis[NCT05746845] | 120 participants (Anticipated) | Observational | 2023-03-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluoxetine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
Treatment options of cognitive impairment in multiple sclerosis.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Fluoxetine; Humans; Interferon-beta; Memantine; Mult | 2010 |
3 trials available for fluoxetine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, C | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Aspartic Acid; Cerebral Corte | 2006 |
13 other studies available for fluoxetine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Letter to the editor: FLOUX-PMS study sample considerations.
Topics: Demyelinating Diseases; Fluoxetine; Humans; Multiple Sclerosis | 2019 |
Response to Grech et al.: FLOUX-PMS study sample considerations.
Topics: Demyelinating Diseases; Fluoxetine; Humans; Multiple Sclerosis | 2019 |
[The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro].
Topics: Dendritic Cells; Fluoxetine; Humans; Interleukin-1beta; Interleukin-6; Multiple Sclerosis | 2020 |
The role of 5-HT
Topics: Adult; Female; Fluoxetine; Humans; Male; Multiple Sclerosis; Receptor, Serotonin, 5-HT2B; Selective | 2021 |
Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; Child, Preschool; Cross-Sec | 2019 |
Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark?
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Humans; Multiple Sclerosis; Neuroprotective | 2019 |
Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.
Topics: Astrocytes; Axons; Brain; Diffusion Magnetic Resonance Imaging; Female; Fluoxetine; Humans; Magnetic | 2008 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Inhibition by fluoxetine of cytochrome P450 2D6 activity.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; | 1993 |
Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.
Topics: Adult; Affective Symptoms; Aged; Brain Injuries; Cerebrovascular Disorders; Crying; Fluoxetine; Huma | 1998 |
The effect of fluoxetine in depression associated with multiple sclerosis.
Topics: Adult; Cognition Disorders; Depressive Disorder; Doxepin; Female; Fluoxetine; Humans; Multiple Scler | 1992 |
Effect of fluoxetine on patients with multiple sclerosis.
Topics: Acute Disease; Depressive Disorder; Fluoxetine; Humans; Multiple Sclerosis | 1991 |
Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine.
Topics: Acute Disease; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Multiple Sclerosis | 1990 |